FDA Commissioner Confirmed Amid Pharmaceutical Industry Ties Controversy

confirmed Importance 8/10 ~1 min read 3 sources 4 actors

Regulatory Capture Executive Power Expansion

Dr. Robert Califf confirmed as FDA Commissioner by a narrow Senate vote of 50-46, highlighting ongoing concerns about pharmaceutical industry regulatory capture. Historical evidence suggests a systemic ‘revolving door’ between FDA and pharmaceutical companies, with approximately 27% of drug reviewers transitioning to industry roles. This pattern creates significant potential conflicts of interest and undermines regulatory oversight capabilities.

Sources & Citations

[1] FDA Chief Confirmed Despite Industry Ties Tier 1

[2] The Revolving Door: FDA to Pharmaceutical Industry Tier 1

[3] FDA Only Inspected 6% of Foreign Drug Manufacturing Facilities in 2022 Tier 1

Tiers Tier 1 court records & gov docs · Tier 2 established outlets · Tier 3 regional & specialty press · Tier 4 opinion or single-source. Methodology →

Cite this entry

The Cascade Ledger. “FDA Commissioner Confirmed Amid Pharmaceutical Industry Ties Controversy.” The Capture Cascade Timeline, March 15, 2022. https://capturecascade.org/event/2022-03-15--pharmaceutical-industry-regulatory-captu-personnel-shift/